Management of Pulmonary Embolism

Raskob, 2014, Thrombosis: a major contributor to global disease burden, Arterioscler Thromb Vasc Biol, 34, 2363, 10.1161/ATVBAHA.114.304488 Wendelboe, 2015, Global public awareness of venous thromboembolism, J Thromb Haemost, 13, 1365, 10.1111/jth.13031 Ceriani, 2010, Clinical prediction rules for pulmonary embolism: a systematic review and meta-analysis, J Thromb Haemost, 8, 957, 10.1111/j.1538-7836.2010.03801.x Konstantinides, 2014, 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism, Eur Heart J, 35, 3033, 10.1093/eurheartj/ehu283 Righini, 2014, Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study, JAMA, 311, 1117, 10.1001/jama.2014.2135 Hutchinson, 2015, Overdiagnosis of pulmonary embolism by pulmonary CT angiography, AJR Am J Roentgenol, 205, 271, 10.2214/AJR.14.13938 Phillips, 2015, Planar and SPECT ventilation/perfusion imaging and computed tomography for the diagnosis of pulmonary embolism: a systematic review and meta-analysis of the literature, and cost and dose comparison, Eur J Radiol, 84, 1392, 10.1016/j.ejrad.2015.03.013 Le Duc-Pennec, 2012, Diagnostic accuracy of single-photon emission tomography ventilation/perfusion lung scan in the diagnosis of pulmonary embolism, Chest, 141, 381, 10.1378/chest.11-0090 Konstantinides, 2012, Pulmonary embolism: risk assessment and management, Eur Heart J, 33, 3014, 10.1093/eurheartj/ehs258 Kearon, 2012, Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, 141, e419S, 10.1378/chest.11-2301 Jaff, 2011, Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association, Circulation, 123, 1788, 10.1161/CIR.0b013e318214914f Laporte, 2008, Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry, Circulation, 117, 1711, 10.1161/CIRCULATIONAHA.107.726232 Aujesky, 2005, Derivation and validation of a prognostic model for pulmonary embolism, Am J Respir Crit Care Med, 172, 1041, 10.1164/rccm.200506-862OC Jiménez, 2010, Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism, Arch Intern Med, 170, 1383, 10.1001/archinternmed.2010.199 Righini, 2011, The Simplified Pulmonary Embolism Severity Index (PESI): validation of a clinical prognostic model for pulmonary embolism, J Thromb Haemost, 9, 2115, 10.1111/j.1538-7836.2011.04469.x Aujesky, 2006, Validation of a model to predict adverse outcomes in patients with pulmonary embolism, Eur Heart J, 27, 476, 10.1093/eurheartj/ehi588 Lankeit, 2011, Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study, Circulation, 124, 2716, 10.1161/CIRCULATIONAHA.111.051177 Aujesky, 2011, Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial, Lancet, 378, 41, 10.1016/S0140-6736(11)60824-6 Zondag, 2011, Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study, J Thromb Haemost, 9, 1500, 10.1111/j.1538-7836.2011.04388.x Agterof, 2010, Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level, J Thromb Haemost, 8, 1235, 10.1111/j.1538-7836.2010.03831.x Hellenkamp, 2015, Risk stratification of normotensive pulmonary embolism based on the sPESI: does it work for all patients?, Int J Cardiol, 197, 162, 10.1016/j.ijcard.2015.06.065 Lankeit, 2014, Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism, Eur Respir J, 43, 1669, 10.1183/09031936.00211613 Jiménez, 2014, Derivation and validation of multimarker prognostication for normotensive patients with acute symptomatic pulmonary embolism, Am J Respir Crit Care Med, 189, 718, 10.1164/rccm.201311-2040OC Meyer, 2014, Fibrinolysis for patients with intermediate-risk pulmonary embolism, N Engl J Med, 370, 1402, 10.1056/NEJMoa1302097 Kaeberich, 2015, Age-adjusted high-sensitivity troponin T cut-off value for risk stratification of pulmonary embolism, Eur Respir J, 45, 1323, 10.1183/09031936.00174514 Dellas, 2014, A novel H-FABP assay and a fast prognostic score for risk assessment of normotensive pulmonary embolism, Thromb Haemost, 111, 996, 10.1160/TH13-08-0663 Bova, 2014, Identification of intermediate-risk patients with acute symptomatic pulmonary embolism, Eur Respir J, 44, 694, 10.1183/09031936.00006114 Fernández, 2015, Validation of a model for identification of patients at intermediate to high risk for complications associated with acute symptomatic pulmonary embolism, Chest, 148, 211, 10.1378/chest.14-2551 Kearon, 2014, Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism, Blood, 123, 1794, 10.1182/blood-2013-12-512681 Agnelli, 2013, Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med, 369, 799, 10.1056/NEJMoa1302507 Schulman, 2014, Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis, Circulation, 129, 764, 10.1161/CIRCULATIONAHA.113.004450 Schulman, 2009, Dabigatran versus warfarin in the treatment of acute venous thromboembolism, N Engl J Med, 361, 2342, 10.1056/NEJMoa0906598 2013, Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism, N Engl J Med, 369, 1406, 10.1056/NEJMoa1306638 2012, Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med, 366, 1287, 10.1056/NEJMoa1113572 2010, Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, 363, 2499, 10.1056/NEJMoa1007903 van Es, 2014, Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials, Blood, 124, 1968, 10.1182/blood-2014-04-571232 Beyer-Westendorf, 2014, Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry, Blood, 124, 955, 10.1182/blood-2014-03-563577 Pollack, 2015, Idarucizumab for dabigatran reversal, N Engl J Med, 373, 511, 10.1056/NEJMoa1502000 Lu, 2013, A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nat Med, 19, 446, 10.1038/nm.3102 Prins, 2015, Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial, Thromb Res, 135, 281, 10.1016/j.thromres.2014.11.008 Bamber, 2015, Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist, Thromb J, 13, 20, 10.1186/s12959-015-0051-3 Klok, 2015, Management of intermediate-risk pulmonary embolism: uncertainties and challenges, Eur J Haematol, 95, 489, 10.1111/ejh.12612 Meyer, 2015, Pulmonary embolism: whom to discharge and whom to thrombolyze?, J Thromb Haemost, 13, S252, 10.1111/jth.12944 Marti, 2015, Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis, Eur Heart J, 36, 10.1093/eurheartj/ehu218 Chatterjee, 2014, Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis, JAMA, 311, 2414, 10.1001/jama.2014.5990 Konstantinides, 2008, Clinical practice. Acute pulmonary embolism, N Engl J Med, 359, 2804, 10.1056/NEJMcp0804570 Wang, 2010, Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial, Chest, 137, 254, 10.1378/chest.09-0765 Sharifi, 2013, Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial), Am J Cardiol, 111, 273, 10.1016/j.amjcard.2012.09.027 Armstrong, 2013, Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction, N Engl J Med, 368, 1379, 10.1056/NEJMoa1301092 Engelberger, 2014, Ultrasound-assisted thrombolysis for acute pulmonary embolism: a systematic review, Eur Heart J, 35, 758, 10.1093/eurheartj/ehu029 Kucher, 2014, Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism, Circulation, 129, 479, 10.1161/CIRCULATIONAHA.113.005544 Piazza, 2015, A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: the SEATTLE II study, J Am Coll Cardiol Intv, 8, 1382, 10.1016/j.jcin.2015.04.020 Kuo, 2015, Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT): initial results from a prospective multicenter registry, Chest, 148, 667, 10.1378/chest.15-0119 Jarrett, 2015, Impact of institutional volume on outcomes of catheter directed thrombolysis in the treatment of acute proximal deep vein thrombosis: a 6-year United States experience (2005-2010), Circulation, 132, 1127, 10.1161/CIRCULATIONAHA.115.015555 Engelberger, 2015, Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis, Circ Cardiovasc Interv, 8, e002027, 10.1161/CIRCINTERVENTIONS.114.002027 Stein, 2011, Increasing use of vena cava filters for prevention of pulmonary embolism, Am J Med, 124, 655, 10.1016/j.amjmed.2011.02.021 Stein, 2012, Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism, Am J Med, 125, 478, 10.1016/j.amjmed.2011.05.025 Muriel, 2014, Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk, J Am Coll Cardiol, 63, 1675, 10.1016/j.jacc.2014.01.058 Mismetti, 2015, Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial, JAMA, 313, 1627, 10.1001/jama.2015.3780 Jia, 2015, Caval penetration by inferior vena cava filters: a systematic literature review of clinical significance and management, Circulation, 132, 944, 10.1161/CIRCULATIONAHA.115.016468 Shiraev, 2013, Trends in pulmonary embolism morbidity and mortality in Australia, Thromb Res, 132, 19, 10.1016/j.thromres.2013.04.032 Dentali, 2016, Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy, Thromb Haemost, 115, 399, 10.1160/th15-02-0172 Agarwal, 2015, Gender disparities in outcomes and resource utilization for acute pulmonary embolism hospitalizations in the United States, Am J Cardiol, 116, 1270, 10.1016/j.amjcard.2015.07.048 Yang, 2011, Pulmonary embolism incidence and fatality trends in Chinese hospitals from 1997 to 2008: a multicenter registration study, PLoS One, 6, e26861, 10.1371/journal.pone.0026861 Park, 2009, Recent trends in clinical outcomes and resource utilization for pulmonary embolism in the United States: findings from the nationwide inpatient sample, Chest, 136, 983, 10.1378/chest.08-2258 Wiener, 2011, Time trends in pulmonary embolism in the United States: evidence of overdiagnosis, Arch Intern Med, 171, 831 Pütter, 2015, Prescription of enoxaparin is associated with decreasing pulmonary embolism mortality rate in Germany, J Thromb Thrombolysis, 40, 468, 10.1007/s11239-015-1265-8 de Miguel-Diez, 2014, Trends in hospital admissions for pulmonary embolism in Spain from 2002 to 2011, Eur Respir J, 44, 942, 10.1183/09031936.00194213 Provias, 2014, The Massachusetts General Hospital Pulmonary Embolism Response Team (MGH PERT): creation of a multidisciplinary program to improve care of patients with massive and submassive pulmonary embolism, Hosp Pract (1995), 42, 31, 10.3810/hp.2014.02.1089 Tsai, 2012, Trends in in-hospital deaths among hospitalizations with pulmonary embolism, Arch Intern Med, 172, 960, 10.1001/archinternmed.2012.198 Carrier, 2010, Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies, J Thromb Haemost, 8, 1716, 10.1111/j.1538-7836.2010.03938.x Mahan, 2012, Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates, Thromb Haemost, 108, 291, 10.1160/TH12-03-0162 Temme, 2015, Noninvasive imaging of early venous thrombosis by 19F magnetic resonance imaging with targeted perfluorocarbon nanoemulsions, Circulation, 131, 1405, 10.1161/CIRCULATIONAHA.114.010962 Stein, 2012, Diagnosis and management of isolated subsegmental pulmonary embolism: review and assessment of the options, Clin Appl Thromb Hemost, 18, 20, 10.1177/1076029611422363 Le Gal, 2015, Controversies in the diagnosis of venous thromboembolism, J Thromb Haemost, 13, S259, 10.1111/jth.12937 Heit, 2000, Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study, Arch Intern Med, 160, 809, 10.1001/archinte.160.6.809 Timp, 2013, Epidemiology of cancer-associated venous thrombosis, Blood, 122, 1712, 10.1182/blood-2013-04-460121 Carrier, 2015, Screening for occult cancer in unprovoked venous thromboembolism, N Engl J Med, 373, 697, 10.1056/NEJMoa1506623 Lee, 2015, Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial, JAMA, 314, 677, 10.1001/jama.2015.9243 Prins, 2014, Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials, Lancet Haematol, 1, e37, 10.1016/S2352-3026(14)70018-3 Vedovati, 2015, Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis, Chest, 147, 475, 10.1378/chest.14-0402 van Es, 2015, Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study, Thromb Haemost, 114, 1268, 10.1160/TH15-06-0452 Crosby, 2013, Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates, Arterioscler Thromb Vasc Biol, 33, 1670, 10.1161/ATVBAHA.113.301282 Zhang, 2010, Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk, Blood, 116, 4684, 10.1182/blood-2010-04-277798 Büller, 2015, Factor XI antisense oligonucleotide for prevention of venous thrombosis, N Engl J Med, 372, 232, 10.1056/NEJMoa1405760 Tosetto, 2012, Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH), J Thromb Haemost, 10, 1019, 10.1111/j.1538-7836.2012.04735.x Eichinger, 2010, Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model, Circulation, 121, 1630, 10.1161/CIRCULATIONAHA.109.925214 Rodger, 2008, Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy, CMAJ, 179, 417, 10.1503/cmaj.080493 Klok, 2015, Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism, J Thromb Thrombolysis Riva, 2014, Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study, Thromb Haemost, 112, 511, 10.1160/TH14-01-0081 Palareti, 2014, D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study, Blood, 124, 196, 10.1182/blood-2014-01-548065 Kearon, 2015, D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study, Ann Intern Med, 162, 27, 10.7326/M14-1275 Couturaud, 2015, Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial, JAMA, 314, 31, 10.1001/jama.2015.7046 Schulman, 2013, Extended use of dabigatran, warfarin, or placebo in venous thromboembolism, N Engl J Med, 368, 709, 10.1056/NEJMoa1113697 Agnelli, 2003, Extended oral anticoagulant therapy after a first episode of pulmonary embolism, Ann Intern Med, 139, 19, 10.7326/0003-4819-139-1-200307010-00008 Agnelli, 2013, Apixaban for extended treatment of venous thromboembolism, N Engl J Med, 368, 699, 10.1056/NEJMoa1207541 Klok, 2014, The post-PE syndrome: a new concept for chronic complications of pulmonary embolism, Blood Rev, 28, 221, 10.1016/j.blre.2014.07.003 Lang, 2013, Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding, Eur Respir J, 41, 462, 10.1183/09031936.00049312 Guérin, 2014, Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism, Thromb Haemost, 112, 598, 10.1160/TH13-07-0538